Company / SG&A Expense
KYNTRA BIO, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$49.3M
FY2025
5-year range
$49.3M / $135.5M
FY2021-FY2025
Trend
-43.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $37M in FY2016 to $135M in FY2021.
Based on SEC 10-K filings.
$49M in FY2025 with a 5-year CAGR of -5.0%.
Improved from $124M to $49M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -22.6%
- 5-Year CAGR
- -5.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -5.0%, indicating a declining trend.
- In FY2025, sg&a expense decreased 43.0% year-over-year.
- Peak sg&a expense was recorded in FY2021.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $49.3M | -43.0% |
| FY2024 | $86.5M | -30.2% |
| FY2023 | $123.9M | +16.5% |
| FY2022 | $106.4M | -21.5% |
| FY2021 | $135.5M | +112.3% |
| FY2020 | $63.8M | +23.3% |
| FY2019 | $51.8M | +12.5% |
| FY2018 | $46.0M | +3.7% |
| FY2017 | $44.4M | +20.2% |
| FY2016 | $36.9M | +51.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026